Development and validation of a highly sensitive method for the determination of abiraterone in rat and human plasma by LC-MS/MS-ESI: Application to a pharmacokinetic study

Biomedical Chromatography

Volumn 26, Issue 6, 2012, Pages 761-768

  Gurav, Sandip ^a   Punde, Ravindra ^a   Farooqui, Junaid ^a   Zainuddin, Mohd ^a   Rajagopal, Sriram ^a   Mullangi, Ramesh ^a  

^a JUBILANT BIOSYS LTD   (India)

Author keywords

Abiraterone; Human plasma; LC MS MS; Method validation; Pharmacokinetics; Rat plasma

Indexed keywords

EXTRACTION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PHARMACOKINETICS; PLASMA (HUMAN); POSITIVE IONS; PRECIPITATION (CHEMICAL); RATS;

ABIRATERONE; HUMAN PLASMAS; INTERNAL STANDARDS; LC-MS-MS; LC.MS/MS; METHOD VALIDATIONS; PHARMACOKINETIC STUDIES; RAPID ASSAY; RAT PLASMA; SENSITIVE METHOD;

ELECTROSPRAY IONIZATION;

ABIRATERONE; PHENACETIN;

ACCURACY; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ISOLATION; ELECTROSPRAY; FOOD AND DRUG ADMINISTRATION; HUMAN; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY COUPLED TO TANDEM MASS SPECTROMETRY AND ELECTROSPRAY IONIZATION; MALE; NONHUMAN; PRACTICE GUIDELINE; RAT; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; VALIDATION STUDY;

RATTUS;

EID: 84860455458     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.1726     Document Type: Article

References (10)

1. Auchus RJ. Overview of dehydroepiandrosterone biosynthesis. Seminars in Reproductive Medicine 2004; 22: 281-288.
2. Barrie SE, Potter GA, Goddard PM, Haynes BP, Dowsett M and Jarman M. Pharmacology of novel steroidal inhibitors of cytochromeP450(17)α (17α-hydroxylase/C17-20 lyase). The Journal of Steroid Biochemistry and Molecular Biology 1994; 50: 267-273.
3. 17α inhibitors. The Journal of Steroid Biochemistry and Molecular Biology 1997; 60: 347-351.
4. Bonfiglio R, King RC, Olah TV and Merkle K. The effects of sample preparation methods on the variability of the electrospray ionization response for model drug compounds. Rapid Communications in Mass Spectrometry 1999; 13: 1175-1185.
5. FDA. Zytiga (abiraterone acetate). Pharmacology/Toxicology Review, 2011. Available from:
6. Hellerstedt BA and Pienta KJ. The current state of hormonal therapy for prostate cancer. CA: a Cancer Journal of Clinicians 2002; 52:154-179.
7. Jemal A, Murray T, Samuels A, Ghafoor A, Ward T and Thun MJ. Cancer statistics. CA: a Cancer Journal of Clinicians 2003; 53: 5-26.
8. Martins V, Asad Y, Wilsher N and Raynaud F. A validated liquid-chromatographic mass spectroscopy method for the quantification of abiraterone acetate and abiraterone in human plasma. Journal of Chromatography B 2006; 843: 262-267.
9. 17, 20-lyase): potential agents for the treatment of prostatic cancer. Journal of Medicinal Chemistry 1995; 38: 2463-2471.
10. US DHHS, FDA and CDER. Guidance for Industry: Bioanalytical Method Validation. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research and Center for Veterinary Medicine, 2001. Available at: